Is BioCryst Pharmaceuticals, Inc. (BCRX) a Buy, Sell, or Hold?
BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRX
$9.74 USD
-$0.17 (-1.72%)
- Volume
- 0
- Average Volume
- 5.05M
- Market Capitalization
- $2.04B
- P/E Ratio
- -5.63
- Dividend Yield
- 0.00%
- Price Target
- $17.00
- Year High
- $11.22
- Year Low
- $6.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.91
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Charles K. Gayer |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | BCRX |
| CUSIP | 09058V103 |
| CIK | 0000882796 |
| Web | https://www.biocryst.com |
| Phone | 919 859 1302 |
| Currency | USD |
| Employees | 435 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -1.55 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.91 |
| Quick Ratio | 1.88 |
| Cash Ratio | 0.88 |
Sales & Book Value
| Annual Sales | $874.84M |
| Price / Sales | 2.31 |
| Cash Flow | 1.21 |
| Price / Cash Flow | 6.95 |
| Price / Book | -4.26 |
Price Target and Rating
| Average Stock Price Forecast | $17.00 |
| High Stock Price Forecast | $29.00 |
| Low Stock Price Forecast | $14.00 |
| Forecast Upside/Downside | -42.71% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 29 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $1.21 |
| Trailing P/E Ratio | -5.63 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $263.86M |
| Net Margin | -51.71% |
| Pretax Margin | -51.28% |
| Return on Equity | 123.57% |
| Return on Assets | -98.48% |
Financials Score
| AltmanZ Score | -5.74 |
| Piotroski Score | 3.00 |
| Working Capital | 178.23M |
| Total Assets | 465.05M |
| Ebit | -379.02M |
| Market Cap | 2.19B |
| Total Liabilities | 1.02B |
Poll Results
About BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA depen ... dent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
Wall Street Analysts Think BioCryst (BCRX) Could Surge 117.96%: Read This Before Placing a Bet
2026-07-14 10:56:18
The consensus price target hints at an 118% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
BioCryst (BCRX) Surges 8.1%: Is This an Indication of Further Gains?
2026-07-08 11:16:12
BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-02 07:00:00
RESEARCH TRIANGLE PARK, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted nine newly-hired employees stock options to purchase an aggregate of 33,950 shares, and restricted stock units (RSUs) covering an aggregate of 91,750 shares, of BioCryst common stock. The options and RSUs were granted as of July 1, 2026, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
BioCryst scraps internal drug discovery programs, leans on partnerships to cut costs
2026-06-29 08:21:45
BioCryst Pharmaceuticals said on Monday it would wind down its internal drug discovery programs and close its Alabama research facility by the end of 2026, as it pivots to external partnerships to build its rare-disease pipeline and streamline expenses.
2026-06-29 07:00:00
—Advances strategic shift toward a disciplined research model prioritizing external innovation to accelerate rare disease pipeline growth—
BioCryst Pharmaceuticals: Management's Plans For Multibillion HAE Franchise Add Up
2026-06-15 13:59:19
BioCryst Pharmaceuticals, Inc. is upgraded to Buy, reflecting strong execution in HAE and a compelling pipeline with Orladeyo and navenibart. BCRX targets $1.8bn in revenues and $1bn in cash by 2033, leveraging best-in-class efficacy and less frequent dosing for navenibart to challenge market incumbents. Recent Q1 results showed 11% YoY Orladeyo revenue growth, robust non-GAAP profitability, and reaffirmed 2026 guidance, suggesting valuation remains attractive.
2026-06-12 07:00:00
— Growing body of ORLADEYO ® clinical data and real-world evidence demonstrates consistent reductions in HAE attack burden and healthcare utilization across diverse patient populations
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-09 16:05:00
RESEARCH TRIANGLE PARK, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted nine newly-hired employees stock options to purchase an aggregate of 33,950 shares, and restricted stock units (RSUs) covering an aggregate of 80,650 shares, of BioCryst common stock. The options and RSUs were granted as of June 1, 2026, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Frequently Asked Questions
-
What is the current BioCryst Pharmaceuticals, Inc. (BCRX) stock price?
-
BioCryst Pharmaceuticals, Inc.(NASDAQ:BCRX) stock price is $9.74 in the last trading session. During the trading session, BCRX stock reached the peak price of $11.22 while $6 was the lowest point it dropped to. The percentage change in BCRX stock occurred in the recent session was --1.72% while the dollar amount for the price change in BCRX stock was -$-0.17.
-
BCRX's industry and sector of operation?
-
The NASDAQ listed BCRX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BCRX?
-
Alane Barnes | Senior Vice President, Chief Legal Officer & Corporate Secretary
Charles K. Gayer | CEO, President & Director
Babar Ghias | Chief Financial Officer & Head of Corporate Development
John Ruesch | Chief Technical Operations Officer
Philip George | Chief Strategy Officer -
How many employees does BCRX have?
-
Number of BCRX employees currently stands at 435. BCRX operates from 4505 Emperor Boulevard, Durham, NC 27703, US.
-
Link for BCRX official website?
-
Official Website of BCRX is: https://www.biocryst.com
-
How do I contact BCRX?
-
BCRX could be contacted at phone #919 859 1302 and can also be accessed through its website. BCRX operates from 4505 Emperor Boulevard, Durham, NC 27703, US.
-
How many shares of BCRX are traded daily?
-
The average number of BCRX shares traded daily for last 3 months was 5.05M.
-
What is the market cap of BCRX currently?
-
The market value of BCRX currently stands at $2.04B with its latest stock price at $9.74